Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Current performance may be lower or higher than the performance data quoted.
Eli Lilly and Company, the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from two pivotal phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist
Frequently Asked Questions How long does a 10mg vial of Melanotan 2 last
Tirzepatide's dual GLP-1/GIP mechanism engages additional appetite-control pathways in the brain and gut
US$ 22.09
US$ 21.04
US$ 27.51
US$ 28.79
US$ 25.79
